Longitudinal Analyses of Antibody Responses to SARS-CoV-2

项目1摘要 我们将对目前或过去的受试者进行全面的免疫反应研究。 感染SARS-CoV-2。首要目标是了解对CoV-2的免疫反应 感染提供了对未来COVID19重复发作的保护，以及CoV-2免疫是否长久 经久不衰。我们提出的假设是，一旦有免疫能力的人有任何形式的 COVID19，他们再也不会患上完全的疾病了。另一方面，CoV-2的长期随访研究 癌症患者或任何免疫缺陷原因患者的免疫将包括寻找再感染和 COVID19病毒的重播。很明显，需要准确的血清学分析来确定谁在给定的 社区感染了SARS CoV-2。在大流行早期上市的许多化验方法容易出现 假阳性和假阴性结果。我们计划验证我们的高效和灵敏的常规免疫分析 SARS冠状病毒2型感染的血清学诊断应该承认，即使是最好的化验也会错过不同寻常的结果。 经聚合酶链式反应检测呈阳性，但抗体检测呈阴性的病例。虽然抗体 化验结果可能是假阴性，也有可能是这个人真的感染了没有发展 体液免疫。在项目2中，我们将测试T细胞免疫测定是否可能证实 即使是一些抗体阴性的患者也对病毒有免疫力。

Project 1 Summary We will conduct comprehensive studies of immune responses in human subjects who have current or past infections with SARS-CoV-2. An overarching aim is to understand whether immune responses to CoV-2 infections confer protection against future repeat episodes of COVID19 and whether CoV-2 immunity is long lasting. We propose the hypothesis that once immunocompetent human beings have had any form of COVID19, they will never get the full disease again. On the other hand, long term follow-up studies of CoV-2 immunity in patients with cancer or any cause of immunodeficiency will include plans to look for reinfection and repeat episodes of COVID19. There is a clear need for accurate serologic assays to determine who in a given community has had infection with SARS CoV-2. Many assays marketed early in the pandemic are prone to false positive and negative results. We plan to validate our efficient and sensitive immunoassays for routine serodiagnosis of SARS CoV-2 infections. It should be admitted that even the best assay is going miss unusual cases where a person tested positive by PCR but shows up negative in antibody tests. Although the antibody assay could be falsely negative, it is also possible that the person was truly infected by did not develop humoral immunity. In project 2, we will test the possibility that measuring T cell immunity may confirm that even some antibody negative patients have immunity to the virus after all.